


# Retriever Medical Receives Another U.S. patent for its Revolutionary Thrombectomy Systems

*Retriever Medical secures additional U.S. patent for its cutting-edge Thrombectomy Systems, reinforcing its position as a leader in medical innovation.*

LAS VEGAS, NV, UNITED STATES, April 16, 2024 /EINPresswire.com/ -- [Retriever Medical](#), Inc., a leading developer of interventional medical systems and devices, proudly announces the issuance of U.S. Pat. No. 11,957,367 for its groundbreaking thrombectomy systems. The patent covers seminal mechanical and aspiration features of the thrombectomy systems.



U.S. Pat. No. 11,957,367 underscores Retriever Medical's commitment to advancing patient care through innovative surgical solutions. As [Ben Bobo](#), CEO of Retriever Medical, states, "This patent

“

The issuance of this patent is a significant milestone for Retriever Medical, highlighting our relentless pursuit of innovation in interventional medicine. ”

*Ben Bobo*

is a pivotal milestone for us, providing robust protection for our transformative thrombectomy system. It reaffirms our dedication to pushing the boundaries of interventional medicine and improving patient outcomes."

Retriever Medical's thrombectomy systems are meticulously engineered to effectively remove the entire spectrum of thrombus, encompassing acute, sub-acute, and chronic conditions, with unparalleled precision and efficacy. The patented technology enables mechanical

expansion and contraction of expandable elements through a unique handle interface, offering unparalleled control and maneuverability during procedures.

The issuance of U.S. Pat. No. 11,957,367 further enhances Retriever Medical's robust intellectual property portfolio covering its thrombectomy systems, which now comprises ten (10) issued U.S. and two (2) international patents (totaling 132 issued patent claims), and over twenty (20) pending U.S. and foreign patent applications. Retriever Medical remains steadfast in its commitment to innovation and excellence, steadfastly pioneering advancements in healthcare.

For more information about Retriever Medical and its groundbreaking thrombectomy systems, please visit [www.rtvmed.com](http://www.rtvmed.com).

About Retriever Medical: Retriever Medical, Inc. is dedicated to transforming interventional medicine by developing innovative surgical solutions, including the revolutionary ClotHound™ ACE thrombectomy systems. With a strong commitment to innovation and patient care, Retriever Medical remains at the forefront of advancing healthcare.

Investor Contact: Ben Bobo Phone: 714.654.2367 Email: [bbobo@rtvmed.com](mailto:bbobo@rtvmed.com)

Safe Harbor Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are

based on current information and belief and are not guarantees of future performance. Actual results may differ materially from those indicated by forward-looking statements due to various risks and uncertainties. For more information on the risks and uncertainties associated with Retriever Medical's business, please refer to the Company's periodic Securities and Exchange Commission filings.

Retriever Medical and the Retriever Medical logo, ClotHound, ClotHound Blue, ClotHound Gold, ClotHound ACE, Clear ACE, ACE, VORS, and Blood Genie are trademarks of Retriever Medical. DogCurve, DogLeg, and DogTail are registered trademarks.

Ben Bobo  
Retriever Medical, Inc.  
+1 7146542367

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/703842475>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.